MDGL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

310.71M

+200.72%

-0.464

-82.87%

306.05M

+122.99%

-0.733

-77.91%

353.35M

+66.05%

0.345

-118.16%

Estimates Revision

The market is revising Upward the revenue expectations for Madrigal Pharmaceuticals, Inc. (MDGL) for FY2025, with the revenue forecasts being adjusted by 8.29% over the past three months. During the same period, the stock price has changed by 19.66%.

Revenue Estimates for FY2025

Revise Upward

+8.29%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+11.71%

In Past 3 Month

Stock Price

Go Up

+19.66%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast MDGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 543.25 USD with a low forecast of 392.00 USD and a high forecast of 650.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

392.00

Averages

543.25

High

650.00

Current: 0.000

Low

392.00

Averages

543.25

High

650.00

Wolfe Research

Outperform -> Peer Perform

downgrade

2026-01-06

New

Reason

Wolfe Research

Price Target

2026-01-06

New

downgrade

Outperform -> Peer Perform

Reason

Wolfe Research downgraded Madrigal Pharmaceuticals to Peer Perform from Outperform.

Wolfe Research

Andy Chen

Outperform

Peer Perform

downgrade

$579

2026-01-06

New

Reason

Wolfe Research

Andy Chen

Price Target

$579

2026-01-06

New

downgrade

Outperform

Peer Perform

Reason

As previously reported, Wolfe Research analyst Andy Chen downgraded Madrigal Pharmaceuticals to Peer Perform from Outperform and removed the firm's prior $579 price target. The firm has heard a range of buyside expectation between $4B and $6B peak sales and even on $6B peak sales believes the stock is trading at "the tippy top" valuation after outperformance in November and December, the analyst tells investors. The firm also cites poor Inventiva patent strength.

Piper Sandler

upgrade

$540 -> $900

2025-12-19

Reason

Piper Sandler

Price Target

$540 -> $900

2025-12-19

upgrade

Reason

Piper Sandler raised the firm's price target on Madrigal Pharmaceuticals to $900 from $540 and keeps an Overweight rating on the shares. The firm notes Madrigal has been trading up, about 75% since August, following REZDIFFRA's weight-threshold dosing patent extended IP protection out to 2045. Subsequently, this raises the question of where the stock will go in 2026. Keeping this in mind, Piper took this opportunity to revisit its model and updated its price target given its increased conviction in REZDIFFRA's lucrative MASH opportunity, both in the F2/F3 and F4 populations.

BofA

Jason Zemansky

Neutral

maintain

$456 -> $581

2025-12-16

Reason

BofA

Jason Zemansky

Price Target

$456 -> $581

2025-12-16

maintain

Neutral

Reason

BofA analyst Jason Zemansky raised the firm's price target on Madrigal Pharmaceuticals to $581 from $456 and keeps a Neutral rating on the shares. The firm is increasing its near-term Rezdiffra forecasts after having conducted a small prescriber survey, but remains below long-term consensus, the analyst tells investors.

B. Riley

William Wood

NULL -> Buy

maintain

$560 -> $670

2025-12-11

Reason

B. Riley

William Wood

Price Target

$560 -> $670

2025-12-11

maintain

NULL -> Buy

Reason

B. Riley analyst William Wood raised the firm's price target on Madrigal Pharmaceuticals to $670 from $560 and keeps a Buy rating on the shares. MASH is now valued using a risk-adjusted approach aligned with recent M&A deals, reflecting peak-year sales of $4.5B extended by loss of exclusivity protection and the Rezdiffra/'2086 combo strategy, the analyst tells investors in a research note. Early GLP-1 adoption trends and strong patient-level script growth support market expansion, while disciplined opex and modest gross-to-net adjustments underpin significant near-term free cash flow generation, the firm says.

H.C. Wainwright

Buy

maintain

$568 -> $620

2025-11-21

Reason

H.C. Wainwright

Price Target

$568 -> $620

2025-11-21

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Madrigal Pharmaceuticals to $620 from $568 and keeps a Buy rating on the shares. The firm increased penetration assumptions for Rezdiffra after speaking with six key opinion leaders. The leaders reported "robust real-world uptake," with current F2/F3 penetration of liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis averaging 23% in high-volume centers and longer-term expectations of 10%-20%, the analyst tells investors in a research note. Despite pressure from weight loss drugs, the leaders view Rezdiffra as an "effective, liver-directed, oral backbone therapy with broader expansion possibilities based on the future F4c data," contends H.C. Wainwright.

Valuation Metrics

The current forward P/E ratio for Madrigal Pharmaceuticals Inc (MDGL.O) is 726.27, compared to its 5-year average forward P/E of 16.36. For a more detailed relative valuation and DCF analysis to assess Madrigal Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

16.36

Current PE

726.27

Overvalued PE

191.75

Undervalued PE

-159.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-22.72

Current EV/EBITDA

-237.96

Overvalued EV/EBITDA

32.57

Undervalued EV/EBITDA

-78.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

48.00

Current PS

9.90

Overvalued PS

147.49

Undervalued PS

-51.50

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 176.46% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MDGL News & Events

Events Timeline

No data

News

4.5

01-09Barron's

U.S. Markets Finished Higher on Friday; Sandisk Saw Notable Gains

7.5

01-09Newsfilter

Madrigal Secures Exclusive License from Pfizer for Ervogastat with $50M Upfront Payment

4.0

01-07NASDAQ.COM

Madrigal Pharmaceuticals Downgraded to Hold, Shares Drop Over 5%

People Also Watch

Frequently Asked Questions

What is Madrigal Pharmaceuticals Inc (MDGL) stock price today?

The current price of MDGL is 514.06 USD — it has decreased -7.58 % in the last trading day.

What is Madrigal Pharmaceuticals Inc (MDGL)'s business?

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

What is the price predicton of MDGL Stock?

What is Madrigal Pharmaceuticals Inc (MDGL)'s revenue for the last quarter?

Madrigal Pharmaceuticals Inc revenue for the last quarter amounts to 287.27M USD, increased 362.03 % YoY.

What is Madrigal Pharmaceuticals Inc (MDGL)'s earnings per share (EPS) for the last quarter?

Madrigal Pharmaceuticals Inc. EPS for the last quarter amounts to -5.08 USD, increased 3.25 % YoY.

What changes have occurred in the market's expectations for Madrigal Pharmaceuticals Inc (MDGL)'s fundamentals?

How many employees does Madrigal Pharmaceuticals Inc (MDGL). have?

Madrigal Pharmaceuticals Inc (MDGL) has 528 emplpoyees as of January 10 2026.

What is Madrigal Pharmaceuticals Inc (MDGL) market cap?

Today MDGL has the market capitalization of 11.68B USD.